文献速递妇科

香港华人女性宫颈癌患者PIK3CA突变的液体活检

Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
PubMed 文献 · Gynecol Oncol · 2017-06-03

研究纳入117例香港华人原发性浸润性宫颈癌患者,采用微滴数字PCR检测治疗前血浆游离DNA中PIK3CA p.E542K和p.E545K突变,22.2%患者检出突变,突变与中位肿瘤大小显著相关(p<0.01),且与无病生存期和总生存期降低显著相关(p<0.05)。

要点

  • 117例香港华人宫颈癌患者治疗前血浆cfDNA中PIK3CA突变检出率为22.2%。
  • PIK3CA突变状态与中位肿瘤大小显著相关(p<0.01)。
  • 血浆PIK3CA突变与无病生存期和总生存期降低显著相关(p<0.05)。

核心结论

  • 作为液体分子活检,循环PIK3CA突变分析有望细化宫颈癌患者的个体化风险分层,并为个体化治疗研究提供平台。

研究设计与样本

  • 研究纳入117例香港华人原发性浸润性宫颈癌患者,采集治疗前血浆样本,采用微滴数字PCR检测cfDNA中PIK3CA p.E542K和p.E545K突变,并与临床病理特征进行相关性分析。

主要发现

  • 22.2%的患者血浆cfDNA中检出PIK3CA突变(p.E542K或p.E545K)。
  • PIK3CA突变状态与中位肿瘤大小显著相关(p<0.01)。
  • 血浆PIK3CA突变与无病生存期和总生存期降低显著相关(p<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cervical cancer is the fourth most common female cancer worldwide. The prognosis for women with advanced-stage or recurrent cervical cancer remains poor and response to treatment is variable. Standardized management protocols leave little room for individualization. We report on a novel blood-based liquid biopsy for specific PIK3CA mutations as a clinically useful biomarker in patients with invasive cervical cancer. METHODS: One hundred seventeen Hong Kong Chinese women with primary invasive cervical cancer and their pre-treatment plasma samples were investigated. Two PIK3CA mutations, p.E542K and p.E545K were measured in cell free DNA (cfDNA) extracted from plasma using droplet digital PCR. This liquid biopsy of PIK3CA in cervical cancer was correlated to clinico-pathological features to verify the potential of PIK3CA as a clinically useful molecular biomarker for predicting disease prognosis and monitoring for progression. RESULTS: PIK3CA mutations, either p.E542K or p.E545K, were detected in plasma cfDNA from 22.2% of the patients. PIK3CA mutation status was significantly correlated to median tumor size (p<0.01). PIK3CA mutations detected in the plasma were significantly associated with decreased disease-free survival and overall survival (p<0.05). CONCLUSIONS: As a liquid molecular biopsy, analysis of circulating PIK3CA mutations shows promise as a way to refine risk stratification of individual patients with cervical cancer, and provides a platform for further research to offer individualized therapy with the purpose of improving outcomes.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chung TKH, Cheung TH, Yim SF, et al. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. Gynecol Oncol. 2017. PMID: 28587748. doi:10.1016/j.ygyno.2017.05.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。